-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Igp9hy4Vwt1de4bMHLUPQz4I05s+mr515rkTETkpSQIjPkqNpxLEHPqMjA3FST3I Rz8leTHNh93kSyumwe2FiA== 0000000000-05-045234.txt : 20060821 0000000000-05-045234.hdr.sgml : 20060821 20050831131555 ACCESSION NUMBER: 0000000000-05-045234 CONFORMED SUBMISSION TYPE: UPLOAD PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20050831 FILED FOR: COMPANY DATA: COMPANY CONFORMED NAME: MIRACOR DIAGNOSTICS INC CENTRAL INDEX KEY: 0000723906 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 581475517 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: UPLOAD BUSINESS ADDRESS: STREET 1: 9191 TOWNE CENTRE DR STREET 2: STE 400 CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 8584557127 MAIL ADDRESS: STREET 1: 9191 TOWNE CENTRE DRIVE STREET 2: STE 400 CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: MEDICAL DEVICE TECHNOLOGIES INC DATE OF NAME CHANGE: 19950518 FORMER COMPANY: FORMER CONFORMED NAME: CYTOPROBE CORP DATE OF NAME CHANGE: 19930929 PUBLIC REFERENCE ACCESSION NUMBER: 0001019687-04-002868 LETTER 1 filename1.txt Mail Stop 6010 August 31, 2005 M. Lee Hulsebus Miracor Diagnostics, Inc. 9191 Towne Center Drive, Suite 400 San Diego, CA 92122 Re: Miracor Diagnostics, Inc. Registration Statement on Form S-3 Amended August 16, 2005 File Number 333-121487 All documents incorporated by reference Dear Hulsebus: We have reviewed your filing and have the following comments. Where indicated, we think you should revise your document in response to these comments. If you disagree, we will consider your explanation as to why our comment is inapplicable or a revision is unnecessary. Please be as detailed as necessary in your explanation. In some of our comments, we may ask you to provide us with supplemental information so we may better understand your disclosure. After reviewing this information, we may or may not raise additional comments. Please respond to comments not relating to the transaction within 10 business days of the date of this letter or tell us when you will provide a response prior to the expiration of the 10-day period regardless of whether you proceed with your transaction. Form S-3 Where you can find more information, page 16 1. We note that you have filed several reports on Form 8-K since the end of your latest fiscal year which need to be incorporated by reference. Please amend your filing to incorporate these reports. Where You Can Find More Information, page 16 2. Please specifically incorporate by reference the amendments to your Form 10-KSB for the fiscal year ended December 31, 2004 and to your Form 10-QSB for the quarterly period ended March 31, 2005 filed on August 16, 2005. Form 10-KSB/A for the fiscal year ended December 31, 2004 filed August 16, 2005 Consolidated Financial Statements (2) Summary of Significant Accounting Policies Revenue Recognition and Accounts Receivable, F-9 - F-10 3. Please refer to your revised disclosures in response to prior comment 28. Please explain to us your basis for taking bad debts into consideration when recording net revenue. Tell us how you distinguish between charity care and bad debt expense. Tell us the amount of bad debt expense for each period presented, including the nature and amounts deducted from revenue. Explain to us how your recognition of revenue meets the criteria in SAB Topic 13A1 that the price is fixed or determinable and collectibility is reasonably assured. * * * As appropriate, please amend your registration statement in response to these comments. You may wish to provide us with marked copies of the amendment to expedite our review. Please furnish a cover letter with your amendment that keys your responses to our comments and provides any requested supplemental information. Detailed cover letters greatly facilitate our review. We may have additional comments after reviewing your amendment and responses to our comments. You may contact Todd Sherman at (202) 551-3665 or James Rosenberg at (202) 551-3679 if you have questions regarding comments on the financial statements and related matters. Please contact Michael Reedich at (202) 551-3612, or me at (202) 551-3710 with any other questions. Sincerely, Jeffrey Riedler Assistant Director cc: David Wagner, Esq. 8400 East Prentice Avenue, Suite 1500 Greenwood Village, CO 80111 ?? ?? ?? ?? 1 -----END PRIVACY-ENHANCED MESSAGE-----